[Demonstration of delta sleep inducing peptide in a strain of human small cell lung cancer by immunocytology].
Paulin. C C; Charnay. Y Y
Key Findings
- DSIP-like immunoreactivity was detected in a strain of human small cell lung cancer.
- Detection was done using a monoclonal antibody specific to DSIP.
- The presence of DSIP suggests it could play a role in the progression of this cancer.
Practical Outcomes
- For the biohacking community, this research does not provide any actionable dosing, protocol, or safety information about DSIP. It is mainly a basic science observation, so it has little direct relevance to longevity, metabolic health, or performance optimization.
Summary
Scientists found that a brain peptide called delta sleep‑inducing peptide (DSIP) shows up in a type of lung cancer cells when they look at them with a special antibody. The study only shows that the peptide is present and might be involved in the disease, but it doesn't tell us how to use DSIP for health or performance.
Abstract
The "delta sleep inducing peptide" (DSIP) is a regulatory peptide localized in the brain, the hypophysis and some endocrine cells of the gut. The present immunological study, performed with a monoclonal antibody to DSIP, provides evidence for the presence of DSIP-like immunoreactivity (DSIP-LI) in a strain of small cell carcinoma. The specificity of the immunoreaction was assessed by the tests using heterologous antigen known to be secreted by these cells. The DSIP could play a role in the course of this disease.
Study Information
pubmed
1992